Skip to content

Invokana Class Action

Invokana Class Action Settlement and Claims Process

A Canada-wide class action settlement has been reached and approved by the Canadian courts regarding the prescription drugs Invokana, Invokamet, and Invokamet XR. Invokana (canagliflozin) is a prescription medication indicated to lower blood sugar in adults with type 2 diabetes. Invokana is also available in combination with metformin, under the brand name Invokamet.

 

The Long Form notices of this Settlement Approval can be reviewed by clicking the links below:

 

The court-approved Settlement Agreement can be consulted here:

  • [English]
  • [Frenchplease note that this version is not an official translation]

 

The Invokana Class Action Settlement applies to:

(a) all persons resident in Canada as of June, 2022 (see specified applicable dates in the Settlement Agreement) who were prescribed Invokana, Invokamet, and/or Invokamet XR, in Canada (at any time before June 2022); AND

(b) all persons who by virtue of a personal relationship to one or more of such persons described in (a) above have claims for common law or statutory damages.

 

The deadline to submit a Claim Form to Trilogy to seek compensation from this class action was August 14, 2023.  NO NEW INDIVIDUAL “CLAIM FORMS” CAN BE SUBMITTED.

 

Claims Administrator

If you have additional questions about this settlement, please contact Trilogy Class Action Services at:

Trilogy Class Action Services, Claims Administrator for the Invokana® Class Action Settlement https://www.invokanacanadasettlement.com/

117 Queen Street, P.O. Box 1000,
Niagara-on-the-Lake, Ontario L0S 1J0
Tel (toll-free): 1‑877‑400‑1211
Fax: 416-342-1761
claims@trilogyclassactions.ca

 

For more information you should review the Long-Form Notice, provided above in PDF.

 

The types of medical conditions that may qualify Class Members for compensation include acute kidney injury, diabetic ketoacidosis, and lower limb loss, if you began using or filled a prescription for Invokana®, Invokamet®, or Invokamet XR® prior to the dates below AND then experienced the relevant medical conditions prior to the dates below:

  • experienced acute kidney injury, prior to January 25, 2016;
  • experienced diabetic ketoacidosis, prior to May 31, 2016; or
  • experienced lower limb loss, prior to September 6, 2017.

 

If you have previously signed a retainer agreement with Merchant Law Group LLP and submitted a Claim Form to Trilogy prior to the deadline of August 14, 2023, please contact our law firm via heidi@merchantlaw.com  with any questions.

Please note: The information provided on this website is Not Legal Advice. The information may or may not be accurate. The information is for discussion purposes only. Reliance upon any information provided would not be grounds to advance a claim against Merchant Law for providing any advice. In order to get a formal legal opinion upon which you may rely about any specific fact scenario, you would have to first retain the services of a lawyer and request a formal legal opinion.